Moving Beyond the Demo: The Strategic Value of Peer Validation in Technology Selection

In the race to adopt AI and advanced technologies, we’ve come to rely on polished demos, performance benchmarks, and “black box” metrics to guide what we choose to implement. But without knowing how a solution will perform amid the friction of real-world workflows, adoption can feel like a leap of faith.

Early adopters were bold enough to make that jump, charting their own paths with few blueprints to follow. Because of their efforts, the picture has become clearer. Adoption for many solutions has matured to the point where laboratory leaders can rely on clinical ground truth from organizations that have already implemented and scaled these technologies. In turn, today’s labs can often make the most confident technology selections by moving beyond the demo and validating workflow fit through direct conversations with experienced peers.

From ideal state to operational reality

A demo is a vital first step for aligning teams around a shared vision and intended impact. But by design, it showcases technology in a way that’s separated from the complexity of day-to-day operations.

The most value is unlocked when technology functions as part of a living ecosystem. When it comes to digital pathology platforms, that reality often includes mixed scanner fleets, AI applications from multiple vendors, subspecialty-specific requirements, and the relentless pressure of daily sign-out. This is where theoretical performance meets the messy reality of variable specimens, edge cases, and interoperability.

Evaluating a solution in a peer lab’s live environment shifts the focus from what a tool can do to what it takes to run it: integration with scanners, LIS and AI, change management, and performance at scale in the case of digital pathology platforms. That “last mile” is where adoption is won or lost.

What to validate beyond the demo

This broader view is reflected in how independent analysts like KLAS Research assess healthcare technology vendors. Their evaluations focus less on isolated features and more on what it takes to implement, operate, and rely on a solution in practice. KLAS structures customer feedback across six experience dimensions—product, operations, relationship, culture, value, and loyalty—to capture what it’s actually like to work with a vendor over time.

These dimensions can serve as a practical framework when conducting reference calls and site visits:

• Product: Validate robustness, clinical readiness, intuitiveness, interoperability, reliability, and the pace of product innovation. Does it consistently meet user needs in the real-world?
• Operations: Understand what implementation really looks like and how the vendor manages upgrades. Are deployments and updates predictable and low-friction?
• Relationship: Assess the quality of support, executive engagement, and responsiveness. How does the vendor handle evolving requirements and goals?
• Culture: Look for accountability and proactive communication. Does working with the team feel like the right fit?
• Value: Determine whether outcomes achieved justify the total cost, including time, effort, and internal resources.
• Loyalty: Strong vendors become long-term partners. Would the customer make the same decision today, and do they expect to feel the same a year or two from now?

Importantly, peer validation should illuminate more than technology. It should reveal a clear picture of if you will be successful, what could derail momentum, and whether the vendor will be there with you on your journey. 

As advanced technology becomes central to laboratory operations, peer validation has emerged as a distinct strategic advantage. Learning from the experience of others does more than mitigate risk. It accelerates time to value by surfacing proven adoption paths and change management strategies that move technology into routine practice. That perspective is increasingly essential in an era defined by staffing shortages, rising case complexity, and shifting regulatory expectations, where the cost of a misstep is higher than ever.

Consequently, leading labs are no longer just technology adopters; they are contributors to a shared base of operational intelligence. Technology selection becomes less a one-time purchase and more an entry point into a learning network that helps laboratories evolve faster and deliver greater impact on patient care.